SEOUL, Jan. 6 (Korea Bizwire) — The Korea National Institute of Health said Wednesday that it will publicly share its multiomics data, clinical data and human biobank samples from COVID-19 patients.
Multiomics refers to integrated data produced to genetically, functionally, and environmentally understand the collection of particles and cells from human biobank samples.
The institute said that it has acquired clinical data and biobank samples from 300 COVID-19 patients and 120 non-COVID-19 patients through ethical and legal agreement procedures.
Among the 300 infected patients, 243 had mild cases of the disease and 57 were severe.
Acquired human biobank samples include serums, plasmas, urine, phlegm, dielectric DNA and peripheral blood mononuclear cells.
The institute used the collected human biobank samples to produce multiomics data and analysis on blood tests and immune agents.
“This will serve as important data to analyze immune reactions following COVID-19 infections and anticipate the infection’s severity and develop medicines,” the institute said.
M. H. Lee (firstname.lastname@example.org)